BIOMAT Database Logo BIOMAT Database Logo

Cost-effectiveness of stereotactic large-core needle biopsy for nonpalpable breast lesions compared to open-breast biopsy. 2004

J H Groenewoud, and R M Pijnappel, and M E van den Akker-Van Marle, and E Birnie, and T Buijs-van der Woude, and W P Th M Mali, and H J de Koning, and E Buskens
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands. j.groenewoud@erasmusmc.nl

This paper demonstrates that the introduction of large-core needle biopsy (LCNB) replacing needle-localised breast biopsy (NLBB) for nonpalpable (screen-detected) breast lesions could result in substantial cost savings at the expense of a possible slight increase in breast cancer mortality. The cost-effectiveness of LCNB and NLBB was estimated using a microsimulation model. The sensitivity of LCNB (0.97) and resource use and costs of LCNB and NLBB were derived from a multicentre consecutive cohort study among 973 women who consented in getting LCNB and NLBB, if LCNB was negative. Sensitivity analyses were performed. Replacing NLBB with LCNB would result in approximately six more breast cancer deaths per year (in a target population of 2.1 million women), or in 1000 extra life-years lost from breast cancer (effect over 100 years). The total costs of management of breast cancer (3% discounted) are estimated at pound 4676 million with NLBB; introducing LCNB would save pound 13 million. The incremental cost-effectiveness ratio of continued NLBB vs LCNB would be pound 12 482 per additional life-year gained (3% discounted); incremental costs range from pound -21 687 (low threshold for breast biopsy) to pound 74 378 (high sensitivity of LCNB).

UI MeSH Term Description Entries
D008297 Male Males
D008403 Mass Screening Organized periodic procedures performed on large groups of people for the purpose of detecting disease. Screening,Mass Screenings,Screening, Mass,Screenings,Screenings, Mass
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008962 Models, Theoretical Theoretical representations that simulate the behavior or activity of systems, processes, or phenomena. They include the use of mathematical equations, computers, and other electronic equipment. Experimental Model,Experimental Models,Mathematical Model,Model, Experimental,Models (Theoretical),Models, Experimental,Models, Theoretic,Theoretical Study,Mathematical Models,Model (Theoretical),Model, Mathematical,Model, Theoretical,Models, Mathematical,Studies, Theoretical,Study, Theoretical,Theoretical Model,Theoretical Models,Theoretical Studies
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003362 Cost-Benefit Analysis A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. In contrast a cost effectiveness in general compares cost with qualitative outcomes. Cost and Benefit,Cost-Benefit Data,Benefits and Costs,Cost Benefit,Cost Benefit Analysis,Cost-Utility Analysis,Costs and Benefits,Economic Evaluation,Marginal Analysis,Analyses, Cost Benefit,Analysis, Cost Benefit,Analysis, Cost-Benefit,Analysis, Cost-Utility,Analysis, Marginal,Benefit and Cost,Cost Benefit Analyses,Cost Benefit Data,Cost Utility Analysis,Cost-Benefit Analyses,Cost-Utility Analyses,Data, Cost-Benefit,Economic Evaluations,Evaluation, Economic,Marginal Analyses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001707 Biopsy, Needle Removal and examination of tissue obtained through a transdermal needle inserted into the specific region, organ, or tissue being analyzed. Aspiration Biopsy,Puncture Biopsy,Aspiration Biopsies,Biopsies, Aspiration,Biopsies, Needle,Biopsies, Puncture,Biopsy, Aspiration,Biopsy, Puncture,Needle Biopsies,Needle Biopsy,Puncture Biopsies

Related Publications

J H Groenewoud, and R M Pijnappel, and M E van den Akker-Van Marle, and E Birnie, and T Buijs-van der Woude, and W P Th M Mali, and H J de Koning, and E Buskens
Stereotactic large core needle biopsy for all nonpalpable breast lesions?
May 2002, Breast cancer research and treatment,
J H Groenewoud, and R M Pijnappel, and M E van den Akker-Van Marle, and E Birnie, and T Buijs-van der Woude, and W P Th M Mali, and H J de Koning, and E Buskens
Large-core needle biopsy of nonpalpable breast lesions.
May 1999, JAMA,
J H Groenewoud, and R M Pijnappel, and M E van den Akker-Van Marle, and E Birnie, and T Buijs-van der Woude, and W P Th M Mali, and H J de Koning, and E Buskens
Cost-effectiveness of stereotactic vacuum-assisted biopsy for nonpalpable breast lesions.
June 2020, European journal of radiology,
J H Groenewoud, and R M Pijnappel, and M E van den Akker-Van Marle, and E Birnie, and T Buijs-van der Woude, and W P Th M Mali, and H J de Koning, and E Buskens
[Stereotactic large core needle biopsy for the diagnosis of nonpalpable breast lesions: reliable without additional excision biopsy].
May 2003, Nederlands tijdschrift voor geneeskunde,
J H Groenewoud, and R M Pijnappel, and M E van den Akker-Van Marle, and E Birnie, and T Buijs-van der Woude, and W P Th M Mali, and H J de Koning, and E Buskens
Stereotactic core biopsy of nonpalpable breast lesions.
December 1995, Journal of the South Carolina Medical Association (1975),
J H Groenewoud, and R M Pijnappel, and M E van den Akker-Van Marle, and E Birnie, and T Buijs-van der Woude, and W P Th M Mali, and H J de Koning, and E Buskens
Diagnostic performance of stereotactic large core needle biopsy for nonpalpable breast lesions in routine clinical practice.
January 2008, International journal of cancer,
J H Groenewoud, and R M Pijnappel, and M E van den Akker-Van Marle, and E Birnie, and T Buijs-van der Woude, and W P Th M Mali, and H J de Koning, and E Buskens
Stereotactic fine-needle aspiration biopsy for nonpalpable breast lesions.
June 1990, AJR. American journal of roentgenology,
J H Groenewoud, and R M Pijnappel, and M E van den Akker-Van Marle, and E Birnie, and T Buijs-van der Woude, and W P Th M Mali, and H J de Koning, and E Buskens
[Cost-effectiveness of percutaneous core needle breast biopsy (CNBB) versus open surgical biopsy (OSB) of nonpalpable breast lesions: metaanalysis and cost evaluation for German-speaking countries].
February 2008, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin,
J H Groenewoud, and R M Pijnappel, and M E van den Akker-Van Marle, and E Birnie, and T Buijs-van der Woude, and W P Th M Mali, and H J de Koning, and E Buskens
Nonpalpable breast lesions: stereotactic automated large-core biopsies.
August 1991, Radiology,
J H Groenewoud, and R M Pijnappel, and M E van den Akker-Van Marle, and E Birnie, and T Buijs-van der Woude, and W P Th M Mali, and H J de Koning, and E Buskens
Nonpalpable breast lesions: correlation of stereotaxic large-core needle biopsy and surgical biopsy results.
August 1993, Radiology,
Copied contents to your clipboard!